Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Pharmacopsychiatry ; 45(6): 217-22, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22290203

ABSTRACT

OBJECTIVE: This study surveyed the use of adjunctive mood stabilizers (MS) and benzodiazepines (BZD) in older Asian schizophrenia patients and examined their demographic and clinical correlates. METHOD: Information on hospitalized schizophrenia patients aged 55 years or more were extracted from the database of the Research on Asian Psychotropic Prescription Patterns (REAP) study. A total of 1,452 patients from 9 Asian countries and territories was included in the study. The patients' sociodemographic and clinical characteristics and the prescriptions of antipsychotics, MS and BZD were recorded using a standardized protocol and data collection procedure. RESULTS: The frequency of MS prescription was 26.7% in the pooled sample, with 25.5% in 2001, 26.9% in 2004 and 27.7% in 2009. The corresponding figures for BZD were 20.7%, 20.2%, 18.4% and 23.1%, respectively. Multiple logistic regression analysis of the whole sample revealed that patients on MS were younger and more likely to be men and to have extrapyramidal side effects (EPS) and a longer duration of illness. Compared to patients in China, those in Japan were more likely to receive MS, while Korean patents were prescribed less MS. In contrast, there were no significant sociodemographic or clinical correlates of BZD use. Compared to patients in China, their Korean and Singaporean counterparts were more likely to be on BZD. CONCLUSIONS: The use of MS and BZD is not uncommon in older Asian patients with schizophrenia. Given the paucity of empirical data on the efficacy of these agents in individuals with schizophrenia of any age and concerns about added side effects in older patients in particular, the rationale for the prescription of these agents in this population warrants further examination.


Subject(s)
Anticonvulsants/therapeutic use , Asian People/psychology , Benzodiazepines/therapeutic use , Lithium Compounds/therapeutic use , Schizophrenia/drug therapy , Age Factors , Aged , Anticonvulsants/administration & dosage , Drug Prescriptions/statistics & numerical data , Drug Therapy, Combination/statistics & numerical data , Female , Humans , Lithium Compounds/administration & dosage , Male , Middle Aged , Practice Patterns, Physicians'/statistics & numerical data , Sex Characteristics
2.
Pharmacopsychiatry ; 44(4): 135-41, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21710403

ABSTRACT

OBJECTIVE: This study aimed to characterize weight changes in schizophrenia patients taking risperidone as part of a randomized, controlled, open-label clinical trial. METHODS: A total of 374 patients with schizophrenia who had been clinically stabilized following an acute episode were randomly assigned to a 'no-dose-reduction' group (initial optimal therapeutic doses continued throughout the study), a '4-week group' (initial optimal therapeutic doses continued for 4 weeks followed by a half dose reduction that was maintained until the end of the study) or a '26-week group' (initial optimal therapeutic doses continued for 26 weeks followed by a half dose reduction until the end of the study). Participants were assessed monthly using standardized assessment instruments during the first 6 months, and then every 2 months until the last recruited patient completed the 1-year follow-up. Weight gain was defined as gaining at least 7% of initial body weight, weight loss as losing at least 7% of initial body weight. A BMI <18.5 kg m⁻² was defined as underweight, 18.5-24.9 kg m⁻² as normal range, and ≥ 25 kg m⁻² as overweight or obese. RESULTS: At the end of follow-up, of the patients who started within the underweight range (n=22), 77.3% gained weight, whereas 4.5% lost weight. The corresponding figures were 39.6% and 4.8% in patients who started at normal weight (n=273), respectively, and 17.7% and 17.7% in patients who started at overweight (n=79), respectively. At the same time, 59.1% of the patients who started at underweight range went into the normal weight and 13.6% into the overweight/obese range, respectively, while 24.5% of those who started at normal weight went into the overweight/obese range, and 1.1% into underweight range, respectively; 20.3% of those who started at overweight range went into normal weight at the end of the follow-up. Multiple logistic regression analyses revealed that being underweight or normal weight at study entry predicted weight gain compared to being overweight, whereas being overweight at entry was associated with a higher likelihood of weight loss compared to being normal weight. No correlation was found between weight change and dose reduction. CONCLUSIONS: Weight change is a common, long-term, but heterogeneous side effect in risperidone maintenance treatment for stable schizophrenia patients. Special attention should be paid to fluctuations in weight that may occur throughout the course of treatment with risperidone.


Subject(s)
Antipsychotic Agents/adverse effects , Body Weight/drug effects , Overweight/chemically induced , Risperidone/adverse effects , Schizophrenia/drug therapy , Thinness/chemically induced , Adult , Antipsychotic Agents/administration & dosage , Antipsychotic Agents/therapeutic use , Body Mass Index , Brief Psychiatric Rating Scale , China , Diagnostic and Statistical Manual of Mental Disorders , Drug Monitoring , Female , Humans , Male , Medication Adherence , Middle Aged , Overweight/complications , Patient Dropouts , Risperidone/administration & dosage , Risperidone/therapeutic use , Schizophrenia/complications , Schizophrenia/physiopathology , Schizophrenia/prevention & control , Secondary Prevention , Socioeconomic Factors , Thinness/complications , Time Factors , Young Adult
3.
Acta Psychiatr Scand ; 113(4): 306-13, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16638075

ABSTRACT

OBJECTIVE: To study the distribution and correlates of body mass index (BMI) among individuals with serious mental illness. METHOD: A total of 169 participants were recruited from randomly selected out-patients receiving community-based psychiatric care and were interviewed with items from the National Health and Nutrition Examination Survey (NHANES) III. Their BMI was compared with that of 2404 matched individuals from the NHANES data set. RESULTS: The distribution of BMI in the psychiatric sample significantly differed from that of the comparison group; 50% of women and 41% of men were obese compared with 27% and 20% in the comparison group. Within the psychiatric sample, higher BMI was associated with current hypertension and diabetes, a wish to weigh less, and reduced health-related functioning. CONCLUSION: Obesity is more prevalent among individuals with serious mental illness than in demographically matched individuals from the US general population. Among persons with mental illness, obesity is associated with co-occurring health problems.


Subject(s)
Mood Disorders/epidemiology , Obesity/diagnosis , Obesity/epidemiology , Schizophrenia/epidemiology , Adolescent , Adult , Aged , Body Mass Index , Drug Therapy/statistics & numerical data , Female , Humans , Male , Middle Aged , Mood Disorders/diagnosis , Mood Disorders/drug therapy , Prevalence , Psychotropic Drugs/therapeutic use , Schizophrenia/diagnosis , Schizophrenia/drug therapy , Severity of Illness Index
SELECTION OF CITATIONS
SEARCH DETAIL
...